Neuralink has received the green light to initiate recruitment for its inaugural human clinical trial, dubbed the PRIME Study (Precise Robotically Implanted Brain-Computer Interface).
Critics argue that the PPPR is marred by contradictions and emphasizes an unwarranted centralization of control at the expense of democracy and human rights.
A study published in the Journal of Exposure Science and Environmental Epidemiology found that women with higher levels of forever chemicals had a greater risk of developing breast, ovary, skin, and uterus cancer.
